ACS chemical neuroscience molecule spotlight on telcagepant (MK-0974)

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Telcagepant (MK-0974) is a novel calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.html). MK-0974 is currently being studied in phase III clinical trials.

Original languageEnglish (US)
Pages (from-to)334-335
Number of pages2
JournalACS Chemical Neuroscience
Volume2
Issue number7
DOIs
StatePublished - Jul 20 2011

Fingerprint

Neurosciences
Molecules
Calcitonin Gene-Related Peptide Receptors
Phase III Clinical Trials
Migraine Disorders
Pipelines
Clinical Trials
Research
telcagepant

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

ACS chemical neuroscience molecule spotlight on telcagepant (MK-0974). / Hopkins, Corey R.

In: ACS Chemical Neuroscience, Vol. 2, No. 7, 20.07.2011, p. 334-335.

Research output: Contribution to journalReview article

@article{f3a27223a6b34e839481ff5fa24a923e,
title = "ACS chemical neuroscience molecule spotlight on telcagepant (MK-0974)",
abstract = "Telcagepant (MK-0974) is a novel calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.html). MK-0974 is currently being studied in phase III clinical trials.",
author = "Hopkins, {Corey R.}",
year = "2011",
month = "7",
day = "20",
doi = "10.1021/cn200059f",
language = "English (US)",
volume = "2",
pages = "334--335",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on telcagepant (MK-0974)

AU - Hopkins, Corey R.

PY - 2011/7/20

Y1 - 2011/7/20

N2 - Telcagepant (MK-0974) is a novel calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.html). MK-0974 is currently being studied in phase III clinical trials.

AB - Telcagepant (MK-0974) is a novel calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.html). MK-0974 is currently being studied in phase III clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=79960726863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960726863&partnerID=8YFLogxK

U2 - 10.1021/cn200059f

DO - 10.1021/cn200059f

M3 - Review article

C2 - 22816019

AN - SCOPUS:79960726863

VL - 2

SP - 334

EP - 335

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 7

ER -